Xenome in third screening partnership

By Pete Young
Wednesday, 27 March, 2002

Brisbane biotech and animal venom specialist Xenome Ltd has found yet another partner to screen its library of bioactive peptide molecules.

Its latest agreement, the third signed in less than a month, is with Icagen Inc, a private US company focused on ion channel therapeutics.

Xenome molecules based on structures isolated from venomous species will be screened against the North Carolina company's proprietary ion channel drug targets.

The new partnership is broader in scope than an earlier agreement Xenome negotiated with another ion channel specialist, UK-based Ionix Pharmaceuticals.

Channels regulating the flow of ions in cells are crucial to the development of many diseases.

Xenome has also struck an agreement to test its molecules against Melbourne-based Cytopia Ltd's anti-inflammatory and anti-cancer targets.

The latest collaboration, like the others, will see the partners sharing equally in any IP and commercial rewards which flow from the joint venture.

The various agreements contain exclusive and non-exclusive clauses which have been structured to avoid any conflicts of interest, according to Xenome CEO Tony Evans.

Related News

Frequent nightmares accelerate aging, increase risk of death

Nghtmares independently predict faster biological aging and earlier mortality — even after...

Cardiac organoids bring hope for treating heart disease

Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd